Novel broad-spectrum antibiotic compound prioritized for development in fight against AMR

  12 June 2024

The Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc. have announced a collaboration agreement to co-develop an innovative compound (BWC0977) with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections. GARDP will provide up to US$20 million in technical and financial support for the pharmaceutical and clinical co-development of BWC0977, while Bugworks has granted GARDP manufacturing and commercialization rights for BWC0977 in 146 countries, almost all of which are low- or middle-income (LMICs). BWC0977 has in vitro activity against a broad spectrum of pathogens that lead to serious hospital-acquired infections, including WHO critical priority pathogens, carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The goal of this partnership is to enable access to BWC0977 simultaneously in Western countries and in LMICs with high AMR burden. GARDP’s technical and financial support is tied to the successful completion of key R&D milestones that align with GARDP’s public health objectives.

Further reading: GARDP
Author(s): GARDP
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed